Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells.
Viruses
; 14(12)2022 11 24.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2123875
ABSTRACT
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Vaccination, supported by social and public health measures, has proven efficacious for reducing disease severity and virus spread. However, the emergence of highly transmissible viral variants that escape prior immunity highlights the need for additional mitigation approaches. Heparin binds the SARS-CoV-2 spike protein and can inhibit virus entry and replication in susceptible human cell lines and bronchial epithelial cells. Primary infection predominantly occurs via the nasal epithelium, but the nasal cell biology of SARS-CoV-2 is not well studied. We hypothesized that prophylactic intranasal administration of heparin may provide strain-agnostic protection for household contacts or those in high-risk settings against SARS-CoV-2 infection. Therefore, we investigated the ability of heparin to inhibit SARS-CoV-2 infection and replication in differentiated human nasal epithelial cells and showed that prolonged exposure to heparin inhibits virus infection. Furthermore, we establish a method for PCR detection of SARS-CoV-2 viral genomes in heparin-treated samples that can be adapted for the detection of viruses in clinical studies.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Replicación Viral
/
Heparina
/
Células Epiteliales
/
SARS-CoV-2
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
/
Variantes
Límite:
Humanos
Idioma:
Inglés
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
V14122620
Similares
MEDLINE
...
LILACS
LIS